Once we become hormone refractory (HRPC) there remains only one approved drug to treat our prostate cancer, docetaxel. As with hormone therapy (ADT) docetaxel also stops working after a period. There have been different strategies used to try to deal with this untenable situation, including the use of docetaxel on an intermittent schedule. A recent [...]
Urinary incontinence is a common problem suffered by many of us post both surgery and radiation therapy for prostate cancer. The degree of incontinence varies from no problem all the way to having no control of the urinary function. Men having surgery find that as time progresses post treatment, they do regain levels of urinary [...]
HIFU (high-intensity focused ultrasound) is one of the newer treatments for prostate cancer. Although not yet approved in the United States it has received a lot of press and growing popularity as a primary treatment option. There are a number of European countries already using it as a regular treatment modality and there are a [...]
On Thursday the Senate Appropriations subcommittee on Labor, Health and Human Services, and Education held its FY 2010 NIH budget hearing. There were two particular items of note for the cancer community. When discussing the NIH funding which was received through the economic stimulus package, Senator Harkin questioned if the current two years the NIH [...]
The Department of Urology, University of Tennessee Health Science Center, Memphis, TN, performed a retrospective study designed to evaluate the overall survival (OS) and disease-specific survival (DSS) in men receiving primary androgen-deprivation therapy (PADT) or salvage medical ADT (SADT) for prostate cancer. The study included men who were diagnosed and treated with ADT between July [...]